

PROVISC®

Sodium Hyaluronate 10mg/mL

(Isolated from Streptococcus zooepidemicus) Viscoelastic Solution

Provides the Quality You Demand in a Viscoelastic

– at a price you prefer



Sodium Hyaluronate 1% clinically proven[1]	Savings in excess of 10% possible compared to leading Sodium Hyaluronate Brand[2]	Provided by a leading quality Ophthalmic Company

References 1. Jacob JSH Br J Ophthalmol. 69 567-571 1985 2. BNF March 1995

ProVisc Prescribing Information

Presentation: A syringe containing 0.55mL of sterile, non-pyrogenic, non-inflammatory high molecular weight fraction of sodium hyaluronate (approximately 10.0 mg/mL) dissolved in sodium chloride phosphate buffer. **Uses:** ProVisc is indicated for use as a surgical aid in anterior segment surgical procedures including cataract extraction with intraocular lens (IOL) implantation. **Dosage and Administration:** A cannula or needle is used to inject a sufficient amount of ProVisc viscoelastic solution into the anterior chamber. See data sheet for additional information. **Contraindications:** ProVisc viscoelastic solution should not be used in patients with hypersensitivity to any components in this preparation. **Warnings:** The IOP should be carefully monitored during the postoperative period. Remove ProVisc viscoelastic solution by irrigation and/or aspiration at the close of surgery. Do not overfill the anterior chamber. Do not reuse cannulas. **Pharmaceutical Precautions:** Store in refrigerator (2-8 C). See data sheet for additional information. Legal category (POM). Product Licence Number: PL 0649/0123.

Alcon Laboratories (UK) Ltd,
Pentagon Park,
Boundary Way,
Hemel Hempstead,
Herts HP2 7UD

Alcon®

Biolon™

(1% Sodium hyaluronate)

An ultrapure viscoelastic with a difference at your fingertips..



...and all the consistent properties you have come to expect.

BIOLON™ (1% Sodium hyaluronate)

ABRIDGED PRESCRIBING INFORMATION.

INDICATIONS

Eye surgery, including intraocular lens insertion, intracapsular and extracapsular lens extraction, glaucoma surgery, corneal graft surgery for accidental trauma, retinal detachment and vitreal replacement procedures.

PRESENTATION

Biolon is supplied in sterile disposable syringes containing 0.5 ml or 1.0 ml solution.

DOSAGE AND ADMINISTRATION

Dosage varies with type of surgery. Usually a dose of 0.2 to 0.6 ml is injected into the anterior segment of the eye. Greater amounts are used in the posterior segment.

CONTRAINDICATIONS

When used as recommended, there are no

SPECIAL WARNINGS AND PRECAUTIONS

Precautions are limited to those normally associated with the surgical procedures being performed.

ADVERSE REACTIONS

Biolon is well-tolerated in the human eye. Transient rises of post-operative intraocular pressure have been reported in some cases.

A causal relationship has not been established between Biolon use and postoperative inflammatory reactions (iritis), corneal oedema and corneal decompensation.

INTERACTIONS

None currently known.

INCOMPATIBILITIES

Mixing of quaternary ammonium salts such as benzalkonium chloride with sodium hyaluronate solutions results in formation of a precipitate. Biolon

previously used with medical solutions containing benzalkonium chloride.

MANUFACTURED BY

BioTechnology General (Israel) Ltd.,
Kiryat Weizmann,
Rehovot 76326, Israel.
CE0483

DISTRIBUTED BY

Kestrel Healthcare
Limited
21a Hyde Street,
Winchester,
Hampshire
S023 7DR.



Date of preparation: